A Prospective Randomized Controlled Clinical Trial Comparing the Effects of Somatostatin and Vasopressin for Control of Acute Variceal Bleeding in the Patients with Liver Cirrhosis.
- Author:
Heon Young LEE
1
;
Heon Ju LEE
;
Seung Min LEE
;
Jun Hwan KIM
;
Soon Wook KWEON
;
Byung Seok LEE
;
Nam Jae KIM
Author Information
1. Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea. leehy@hanbat.chungnam.ac.kr
- Publication Type:Original Article ; Clinical Trial ; Comparative Study ; Randomized Controlled Trial
- Keywords:
Variceal bleeding;
Somatostatin;
Vasopressin
- MeSH:
Comparative Study;
Esophageal and Gastric Varices/*drug therapy/etiology;
Female;
Gastrointestinal Hemorrhage/*drug therapy/etiology;
Hemostatics/*administration & dosage/adverse effects;
Human;
Infusions, Intravenous;
Liver Cirrhosis/*complications/mortality/therapy;
Male;
Middle Aged;
Prospective Studies;
Somatostatin/*administration & dosage/adverse effects;
Treatment Outcome;
Vasopressins/*administration & dosage/adverse effects
- From:The Korean Journal of Internal Medicine
2003;18(3):161-166
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Acute variceal bleeding is a serious complication of liver cirrhosis, which has an attendant mortality of approximately 60% over two years, and a variety of treatments, such as balloon tamponade, endoscopic varix ligation, sclerotherapy, histoacryl injection and vasoactive drugs, have been used. The aims of the present trial were to compare the effectiveness and complications of somatostatin and vasopressin in the treatment of acute variceal bleeding. METHODS: Forty-three cirrhotic patients, with endoscopically proven acute variceal bleeding, were included in this trial. Both drugs were given as continuous intravenous infusions for 48 hours. Twenty patients received the somatostatin (250 mcg per hr after a bolus of 50 mcg) and twenty-three the vasopressin (0.4 units per min). RESULTS: There were no significant differences between the two groups in relation to age, sex, etiology of cirrhosis, Child-Pugh classification, characteristics of bleeding episode, laboratory findings before randomization and units of transfused blood during therapy. Rebleeding, within 6 hours after beginning of therapy, was regarded as failure to control initial bleeding, and was observed in 3 (13.0%) of the patients who received vasopressin and in 1 (5.0%) treated with somatostatin (p> 0.05). Five patients in both the somatostatin (25.0%) and vasopressin (21.7%) groups rebled during the first 5 days following the initial therapy (p> 0.05). Meaningful complications related to the use of vasopressin were observed in 5 patients (chest pain or abdominal pain requiring nitroglycerin), but no complications were associated with the use of somatostatin (p< 0.05). The mortalities during hospitalization were similar in both the treatment groups. Two of the vasopressin and 1 of the somatostatin group died due to the uncontrolled rebleeding, and 1 of the vasopressin group died due to hepatic failure (2 weeks later after theropy). CONCLUSION: This study showed no differences in the effectiveness of somatostatin and vasopressin, but the somatostatin group had a lower risk of the complications.
